NCT07333261Active, not recruitingPhase 1
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
A Phase 1b Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Newly Diagnosed Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 2 Dec 2025
- Start date
- 9 Feb 2026
- Primary completion date
- 31 Dec 2031
- Lead sponsor
- Susan Bal
- Diseases
- Multiple myeloma
- NCT number
- NCT07333261
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 25
- From 9 Feb 2026 to the primary completion date, 31 Dec 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known active or history of central nervous system (CNS) involvement of MM.
- Prior history of other malignancies
- Uncontrolled infection
- Other protocol-defined Inclusion/Exclusion criteria apply.
Other
- Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS or clinically significant amiloidosis.
Who the study is looking for
- Age \> 18 years with no upper age limit
- NDMM with indication for initiation of therapy diagnosed within last 12 months. Pretreatment parameters necessary for disease characterization and response assessment must be available.
- Not eligible for ASCT by institutional criteria or deferring ASCT due to personal preference.
- ECOG performance status 0-1
- Adequate organ function
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alabama at Birmingham Coordinator of this site? Confirm its status | Birmingham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.